Ironsides Asset Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$243K Hold
6,623
0.06% 71
2025
Q4
$337K Hold
6,623
0.09% 60
2025
Q3
$368K Buy
+6,623
New +$388K 0.09% 48
2025
Q1
Sell
-6,286
Closed -$541K 69
2024
Q4
$541K Sell
6,286
-472
-7% -$51K 0.16% 40
2024
Q3
$805K Buy
6,758
+3,490
+107% +$465K 0.23% 34
2024
Q2
$466K Hold
3,268
0.16% 38
2024
Q1
$420K Buy
3,268
+436
+15% +$51.9K 0.14% 47
2023
Q4
$293K Sell
2,832
-686
-19% -$67.8K 0.13% 48
2023
Q3
$320K Hold
3,518
0.15% 50
2023
Q2
$285K Hold
3,518
0.12% 59
2023
Q1
$280K Hold
3,518
0.13% 63
2022
Q4
$238K Buy
+3,518
New +$206K 0.11% 70
2022
Q3
Sell
-3,818
Closed -$213K 98
2022
Q2
$213K Hold
3,818
0.08% 78
2022
Q1
$212K Hold
3,818
0.06% 89
2021
Q4
$214K Sell
3,818
-500
-12% -$27.1K 0.06% 87
2021
Q3
$207K Sell
4,318
-570
-12% -$27.6K 0.07% 93
2021
Q2
$205K Sell
4,888
-4,900
-50% -$190K 0.06% 93
2021
Q1
$330K Hold
9,788
0.1% 70
2020
Q4
$342K Sell
9,788
-1,350
-12% -$46.7K 0.11% 65
2020
Q3
$387K Sell
11,138
-4,112
-27% -$137K 0.12% 61
2020
Q2
$499K Hold
15,250
0.16% 57
2020
Q1
$459K Hold
15,250
0.28% 47
2019
Q4
$441K Hold
15,250
0.14% 63
2019
Q3
$394K Buy
+15,250
New +$386K 0.13% 64

Other funds holding NVO

Ironsides Asset Advisors's NVO Position: Q1 2026 in Review

Ironsides Asset Advisors held its Novo Nordisk (NVO) position steady in Q1 2026 at 6,623 shares worth $243K. The position accounts for 0.06% of the portfolio, ranked #71.

Ironsides Asset Advisors first reported a position in NVO in Q3 2019 and has held it in 24 quarters since. The position peaked at $805K in Q3 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Ironsides Asset Advisors held 6,623 shares of Novo Nordisk worth $243K as of Q1 2026.
  • Ironsides Asset Advisors left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.06% of Ironsides Asset Advisors's portfolio in Q1 2026, its #71 holding.
  • Ironsides Asset Advisors first reported a position in Novo Nordisk in Q3 2019 and has held it in 24 quarters since.
  • Ironsides Asset Advisors's Novo Nordisk position peaked at $805K in Q3 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Ironsides Asset Advisors's 13F filing for Q1 2026, filed 11 May 2026.